Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology-Reference-Cited by-同舟云学术

Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology

Published:2015-07-07 Issue:12 Volume:36 Page:9641-9648
ISSN:1010-4283
Container-title:Tumor Biology
language:en
Short-container-title:Tumor Biol.

Author:

Odabas Hatice,Ulas Arife,Aydin Kubra,Inanc Mevlude,Aksoy Asude,Yazilitas Dogan,Turkeli Mehmet,Yuksel Sinemis,Inal Ali,Ekinci Ahmet S.,Sevinc Alper,Demirci Nebi S.,Uysal Mukremin,Alkis Necati,Dane Faysal,Aliustaoglu Mehmet,Gumus Mahmut

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13277-015-3728-0.pdf

Reference20 articles.

1. Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, et al. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer. 2010;46(4):735–43.

2. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095.

3. Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer. 2004;43(2):183.

4. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589–97.

5. Sandoro A, Maiorinol Sandoro M. Second-line treatment with vinorelbine in the weekly monotherapy chemotherapy for the treatment of advanced non-small cell lung cancer. Lung Cancer. 1994;11:130. suppl 1, abstr 497.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First and Second Line Chemotherapeutic Regimens for Non-Small Cell Lung Carcinomas - The Efficacy of Platinum, Non-Platinum and Combination Therapy: A Literature Review;Cureus;2020-11-22

2. The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China;OncoTargets and Therapy;2016-10

3. Treatment Patterns for Advanced Non–Small-cell Lung Cancer After Platinum-containing Therapy in U.S. Community Oncology Clinical Practice;Clinical Lung Cancer;2016-09

4. Response to: Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach?;Current Oncology;2016-04-01

5. Second-Line Treatment of Non-Small-Cell Lung Cancer with Wild-Type EGFR Status. What Is the Best Approach?;Current Oncology;2016-04-01